One significant aspect of prostate cancer is the androgen receptor (AR) signaling pathway which is exploited as a drug target by pharmacologic androgen deprivation or antagonistic AR blockade therapy in certain tumor stages [14–16]. Here, AR is linked to prostate cancer.